HROW
HARROW, INC.Company Information
- Company Name
- HARROW, INC.
- CIK
- CIK0001360214
- Category
- Large accelerated filer
- Ticker: Exchange
- HROW: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- HROW
SEC filing data through
Insider Sentiment
- Last purchase
- 2026-05-18
- Last sale
- 2026-08-14
- Shares purchased (TTM)
- 15,500
- Shares sold (TTM)
- 174,513
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 21,664,804
- Shares outstanding
- 37,350,401
- Ownership
- 58.00%
Earnings Market Reaction
- Filing date
- 2026-08-10
- Price on filing date
- —
- 1-month reaction
- -5.31%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 84 | 95 | 73 | 74 | 53 | 67 | 47 | 73 | 71 | 69 | 74 | 66 | ||||||
| Short Term Investments | - | - | - | - | - | - | - | - | - | 7 | 9 | 8 | ||||||
| Accounts Receivable Net Current | 119 | 101 | 111 | 78 | 79 | 77 | 116 | 54 | 52 | 29 | 36 | 18 | ||||||
| Inventory Net | 17 | 16 | 14 | 13 | 12 | 11 | 11 | 10 | 9 | 11 | 11 | 9 | ||||||
| Prepaid Expense And Other Assets Current | 10 | 14 | 14 | 13 | 12 | 15 | 15 | 11 | 7 | 10 | 10 | 9 | ||||||
| Assets Current | 229 | 226 | 212 | 178 | 155 | 170 | 190 | 147 | 139 | 125 | 139 | 110 | ||||||
| Property Plant And Equipment Net | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 3 | 4 | 4 | ||||||
| Capitalized Computer Software Net | - | - | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | ||||||
| Operating Lease Right Of Use Asset | 7 | 8 | 8 | 8 | 8 | 8 | 9 | 9 | 7 | 7 | 7 | 7 | ||||||
| Intangible Assets Net Excluding Goodwill | 176 | 181 | 175 | 172 | 177 | 181 | 185 | 189 | 155 | 157 | 160 | 163 | ||||||
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Assets | 417 | 420 | 399 | 363 | 345 | 364 | 389 | 352 | 307 | 296 | 312 | 286 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable And Accrued Liabilities Current | 34 | 30 | 42 | 20 | 25 | 39 | 41 | 25 | 22 | 15 | 25 | 13 | ||||||
| Business Combination Contingent Consideration Liability Current | - | - | - | - | - | - | - | 37 | - | - | - | - | ||||||
| Employee Related Liabilities Current | 12 | 9 | 10 | 10 | 7 | 8 | 9 | 7 | 6 | 5 | 5 | 5 | ||||||
| Contract With Customer Liability Current | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Notes Payable Current | - | - | - | - | 184 | 108 | - | - | - | - | - | - | ||||||
| Operating Lease Liability Current | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | ||||||
| Liabilities Current | 102 | 91 | 96 | 65 | 249 | 187 | 91 | 95 | 54 | 42 | 49 | 19 | ||||||
| Operating Lease Liability Noncurrent | 7 | 8 | 8 | 8 | 8 | 9 | 9 | 10 | 7 | 7 | 7 | 7 | ||||||
| Accounts Payable And Accrued Liabilities Noncurrent | - | - | - | - | - | - | - | 3 | 3 | 3 | 3 | 3 | ||||||
| Long Term Notes Payable | 292 | 292 | 243 | 243 | 38 | 113 | 220 | 186 | 185 | 184 | 186 | 182 | ||||||
| Liabilities | 402 | 391 | 347 | 316 | 296 | 308 | 320 | 294 | 248 | 235 | 242 | 211 | ||||||
Stockholders Equity | ||||||||||||||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital | 217 | 213 | 209 | 210 | 214 | 226 | 221 | 216 | 212 | 208 | 205 | 200 | ||||||
| Retained Earnings Accumulated Deficit | -201 | -184 | -157 | -163 | -164 | -169 | -151 | -158 | -154 | -147 | -134 | -125 | ||||||
| Stockholders Equity | 15 | 29 | 52 | 47 | 49 | 56 | 69 | 58 | 58 | 61 | 70 | 75 | ||||||
| Minority Interest | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | ||||||
| Liabilities And Stockholders Equity | 417 | 420 | 399 | 363 | 345 | 364 | 389 | 352 | 307 | 296 | 312 | 286 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 50 | 50 | 50 | 50 | 50 | 50 | 50 | 50 | 50 | 50 | 50 | 50 | ||||||
| Common Stock Shares Issued | 37 | 37 | 37 | 37 | 37 | 36 | 36 | 36 | 35 | 35 | 35 | 35 | ||||||
| Shares Outstanding | 37 | 37 | 37 | 37 | 37 | 36 | 36 | 36 | 35 | 35 | 35 | 35 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialHARROW, INC. (HROW) — SEC Financial Statements & Analysis
HARROW, INC. (HROW) is a pharmaceutical preparations company, incorporated in DE. HARROW, INC. trades on Nasdaq as: HROW. HARROW, INC. (HROW)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-10. Based on that filing, HARROW, INC. carries a market cap of $1.59B, a P/E ratio of -42.61x, a P/B ratio of 104.36x, a P/S ratio of 5.76x, an enterprise value of $1.79B, and an EV/EBITDA multiple of -2039.50x. On profitability, it posts a gross margin of 73.28%, an operating margin of -1.00%, a net margin of -13.51%, a Return on Equity (ROE) of -115.43%, a Return on Assets (ROA) of -9.77%, and a Return on Invested Capital (ROIC) of -1.21%. Per share, it reports EPS of $-1.00, diluted EPS of $-1.00, free cash flow per share of $0.13, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 21.05% year-over-year, net income growth of 263.96% year-over-year, and EPS growth of 258.50% year-over-year. On the balance sheet, it maintains a current ratio of 2.24x, a quick ratio of 1.98x, working capital of $127.14M, a debt-to-equity ratio of 26.45x, a debt ratio of 0.96, an interest coverage ratio of -0.12x, free cash flow of $5.02M (TTM), and net debt of $208.49M. Figures sourced from SEC EDGAR.
- Market Cap
- $1.59B
- P/E TTM
- -42.61x
- EPS TTM
- $-1.00
- P/B TTM
- 104.36x
- ROE TTM
- -115.43%
- ROA TTM
- -9.77%
- Debt To Equity
- 26.45x
- Free Cash Flow TTM
- $5.02M
- Net Revenue TTM Growth 1Y
- 21.05%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is HARROW, INC. in?
HARROW, INC. (HROW) operates in the Pharmaceutical Preparations industry.
What exchange does HROW trade on?
HARROW, INC. (HROW) trades on the Nasdaq.
Where is HARROW, INC. incorporated?
HARROW, INC. is incorporated in DE.
When was HARROW, INC. (HROW)'s most recent SEC filing?
HARROW, INC. (HROW)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-10.
What is HROW's market cap?
HARROW, INC. (HROW) has a market capitalization of $1.59B as of 2026-06-30.
What is HROW's EPS (earnings per share)?
HARROW, INC. (HROW)'s trailing twelve month EPS is $-1.00 as of 2026-06-30.
What is HROW's ROE (return on equity)?
HARROW, INC. (HROW)'s trailing twelve month Return on Equity (ROE) is -115.43% as of 2026-06-30.
What is HROW's ROA (return on assets)?
HARROW, INC. (HROW)'s trailing twelve month Return on Assets (ROA) is -9.77% as of 2026-06-30.
What is HROW's ROIC (return on invested capital)?
HARROW, INC. (HROW)'s trailing twelve month Return on Invested Capital (ROIC) is -1.21% as of 2026-06-30.
What is HROW's EV/EBITDA?
HARROW, INC. (HROW)'s trailing twelve month EV/EBITDA is -2039.50x as of 2026-06-30.